Brett Lauring

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Takeda (United States) · ORCID：0000-0002-9680-7452

发表论文 45 篇 · 总被引 3116 次 · h-index 25

代表论文

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) (2018 · American Heart Journal · 被引 205)
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( VERTIS MET ) (2017 · Diabetes Obesity and Metabolism · 被引 191)
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial (2017 · Diabetes Obesity and Metabolism · 被引 164)
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study (2017 · Diabetes Obesity and Metabolism · 被引 161)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study (2017 · Diabetes Therapy · 被引 155)
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone (2017 · Diabetes Obesity and Metabolism · 被引 146)